Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

JU INSIGHT A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel for BCG-Naïve Nonmuscle-Invasive Bladder Cancer

By: Sunil H. Patel, MD, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Andrew T. Gabrielson, MD, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Sin Chan, BS, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Deborah Schwartz, RN, BSN, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Connie Collins, RN, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Nirmish Singla, MD, MSc, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Bruce Trock, PhD, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Trinity J. Bivalacqua, MD, PhD, Hospital of the University of Pennsylvania, Philadelphia; Noah Hahn, MD, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland Greenberg Bladder Cancer Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Max R. Kates, MD, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland | Posted on: 17 Jul 2024

Patel SH, Gabrielson AT, Chan S, et al. A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of bacillus Calmette-Guérin–naïve nonmuscle-invasive urothelial carcinoma of the bladder. J Urol. 2024;212(1):95-103. doi:10.1097/ JU. 0000000000003977

Study Need and Importance

For decades, the mainstay treatment for patients with high-risk nonmuscle-invasive bladder cancer (NMIBC) has been intravesical treatment with bacillus Calmette-Guérin (BCG). However, amidst widespread BCG shortages researchers have sought alternative treatment options that can be utilized in the BCG-naïve setting. Combination intravesical gemcitabine and docetaxel (GemDoce) has demonstrated efficacy as a second-line therapy for patients with BCG-unresponsive NMIBC. In this context, we performed a prospective single-arm open-label phase 2 trial for patients with BCG-naïve high-risk NMIBC. Intravesical GemDoce was administered weekly for 6 weeks as induction followed by monthly maintenance therapy for 2 years among responders. The primary end point was 3-month complete response rate, and secondary end points included adverse events (AEs) and 12-month complete response rate.

What We Found

Between August 2020 and August 2022 we enrolled 25 patients with median follow-up of 19.6 months. The pretreatment pathologic stages were high-grade (HG) T1 with carcinoma in situ (CIS; n=7), HGT1 without CIS (n=6), HGTa (n=9), and CIS alone (n=3). The 3-month and 12-month CR rates were 100% and 92%, respectively. Two patients with pretreatment HGT1 had HGT1 recurrences at 9 and 12 months. No patients progressed to T2 disease, underwent radical cystectomy, or had radiographic evidence of metastatic disease. Grade 1 AEs were common (23/25 patients) including hematuria, urinary frequency, urgency, and fatigue. Five patients (20%) experienced a Grade 3 AE including hematuria and UTI.

Limitations

This study was single center and single arm, and included a relatively low proportion of patients with CIS.

Interpretation for Patient Care

This single-arm phase 2 trial demonstrates that intravesical GemDoce was well tolerated with promising efficacy for patients with BCG-naïve high-risk NMIBC. These results provide impetus for conducting a prospective phase 3 trial comparing BCG and GemDoce (BRIDGE) in an analogous patient population.

advertisement

advertisement